Legal status in the United States
Is Tirzepatide legal?
Read at FDA, DEA and WADAPublished by PepVault
Tirzepatide is FDA-approved (Mounjaro and Zepbound, first in 2022), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.
Tirzepatide at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Approved (Mounjaro, 2022) |
| Compounding | Approved drug; not in shortage |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Tirzepatide is FDA-approved, as Mounjaro in 2022 and as Zepbound in 2023.
Mounjaro (injection)
Approved for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes. NDA 215866, first approved May 13, 2022.
- Drugs@FDA: Mounjaro, application 215866, U.S. Food and Drug Administration. Read .
- Mounjaro prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
Zepbound (injection)
Approved for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity. NDA 217806, first approved November 8, 2023.
- Drugs@FDA: Zepbound, application 217806, U.S. Food and Drug Administration. Read .
- Zepbound prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Mounjaro, application 215866, U.S. Food and Drug Administration. Read .

Compounding
Tirzepatide is the active ingredient of FDA-approved drugs. FDA wrote on April 1, 2026 that tirzepatide and semaglutide appear neither on the 503B bulks list nor on its drug shortage list, and outsourcing facilities may compound from bulk only what is on that list or in shortage; on April 30, 2026 FDA proposed to keep tirzepatide off the 503B bulks list, finding “no clinical need.” FDA’s conditions for pharmacies under 503A include not compounding, “regularly or in inordinate amounts”, what it calls “essentially copies” of a commercially available drug. Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.
The source: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026), U.S. Food and Drug Administration. Read .
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Used in Compounding (content current as of March 26, 2026), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
The 2026 Prohibited List doesn’t name tirzepatide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Tirzepatide in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Tirzepatide FDA approved?
Tirzepatide is FDA-approved, as Mounjaro in 2022 and as Zepbound in 2023.
Is Tirzepatide a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Tirzepatide banned in sport?
The 2026 Prohibited List doesn’t name tirzepatide or GLP-1 drugs, and S0, the class for unapproved substances, doesn’t reach an approved drug.
What does FDA say about compounding Tirzepatide?
Tirzepatide is the active ingredient of FDA-approved drugs. FDA wrote on April 1, 2026 that tirzepatide and semaglutide appear neither on the 503B bulks list nor on its drug shortage list, and outsourcing facilities may compound from bulk only what is on that list or in shortage; on April 30, 2026 FDA proposed to keep tirzepatide off the 503B bulks list, finding “no clinical need.” FDA’s conditions for pharmacies under 503A include not compounding, “regularly or in inordinate amounts”, what it calls “essentially copies” of a commercially available drug. Being a component of an FDA-approved drug product is one of the three conditions FDA’s page on bulk drug substances gives for 503A.